Cargando…

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients

OBJECTIVES: A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung cancer expressing carcinoembryonic antigen (CEA) to optimize bispecific antibody and labeled peptide doses, as well as the delay between their injections. METHODS: Three...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodet-Milin, Caroline, Ferrer, Ludovic, Rauscher, Aurore, Masson, Damien, Rbah-Vidal, Latifa, Faivre-Chauvet, Alain, Cerato, Evelyne, Rousseau, Caroline, Hureaux, José, Couturier, Olivier, Salaün, Pierre-Yves, Goldenberg, David M., Sharkey, Robert M., Kraeber-Bodéré, Françoise, Barbet, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661432/ https://www.ncbi.nlm.nih.gov/pubmed/26640780 http://dx.doi.org/10.3389/fmed.2015.00084

Ejemplares similares

A pretargeting system for tumor PET imaging and radioimmunotherapy
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Pretargeting for imaging and therapy in oncological nuclear medicine
por: Bailly, Clément, et al.
Publicado: (2017)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
por: Bodet-Milin, Caroline, et al.
Publicado: (2019)

Sensitivity of pretargeted immunoPET using (68)Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with (18)FDG PET-CT
por: Foubert, Fanny, et al.
Publicado: (2018)

Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012)

Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy
por: Woliner-van der Weg, Wietske, et al.
Publicado: (2015)

Immuno-PET for Clinical Theranostic Approaches
por: Bailly, Clément, et al.
Publicado: (2016)

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
por: Bailly, Clément, et al.
Publicado: (2019)

Tumor Immunotargeting Using Innovative Radionuclides
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Cell Tracking in Cancer Immunotherapy
por: Perrin, Justine, et al.
Publicado: (2020)

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
por: Rousseau, Caroline, et al.
Publicado: (2011)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
por: Carlier, Thomas, et al.
Publicado: (2013)

Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region
por: Pallardy, Amandine, et al.
Publicado: (2020)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
por: Schoffelen, R, et al.
Publicado: (2013)

Pretargeted Nuclear Imaging and Radioimmunotherapy Based on the Inverse Electron-Demand Diels–Alder Reaction and Key Factors in the Pretargeted Synthetic Design
por: Qiu, Lin, et al.
Publicado: (2019)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method
por: Schoffelen, Rafke, et al.
Publicado: (2012)

Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials
por: Bailly, Clément, et al.
Publicado: (2016)

From a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450
por: Carlier, Thomas, et al.
Publicado: (2020)

FDG-PET in Follicular Lymphoma Management
por: Bodet-Milin, C., et al.
Publicado: (2012)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma
por: Bailly, Clement, et al.
Publicado: (2017)

Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018)

Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2014)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy
por: Bailly, Clément, et al.
Publicado: (2014)

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases
por: Pichon, Baptiste, et al.
Publicado: (2020)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT(R))
por: De Santis, R, et al.
Publicado: (2003)

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture
por: Bailly, Clément, et al.
Publicado: (2019)

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
por: Bodet-Milin, Caroline, et al.
Publicado: (2023)

Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_umfdmdd2cakjmq0neecsk6dm93